{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/prostatitis-chronic/","result":{"data":{"firstChapter":{"id":"db8b7f60-5def-5da6-8f5a-97b134fe81af","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field fc175275-9440-487a-87ab-c9f191b59308 --><h1>Prostatitis - chronic: Summary</h1><!-- end field fc175275-9440-487a-87ab-c9f191b59308 -->","htmlStringContent":"<!-- begin item 6ddf2816-262a-432f-a8b1-f24c41e8c03b --><!-- begin field df8e4bd4-9e5a-4a3b-85ef-79ffadf21852 --><ul><li>Chronic prostatitis is idefined as at least 3 months of urogenital pain, which may be perineal, suprapubic, inguinal, rectal, testicular, or penile and is often associated with lower urinary tract symptoms (such as dysuria, frequency, hesitancy, and urgency), and sexual dysfunction (erectile dysfunction, painful ejaculation, or postcoital pelvic discomfort).<ul><li>In practice a diagnosis of chronic prostatitis is often suspected after a shorter duration of symptoms.</li></ul></li><li>Chronic prostatitis can be further classified as:<ul><li>Chronic bacterial prostatitis (CBP) — this accounts for about 10% of men with chronic prostatitis.</li><li>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) — this accounts for about 90% of men with chronic prostatitis (in these cases there is no proven bacterial infection).</li></ul></li><li>Men with chronic prostatitis can experience a greatly reduced quality of life.</li><li>In most cases the trend is for symptoms to improve over months or years.</li><li>Chronic prostatitis should be suspected in men with:<ul><li>Urogenital pain for example in the perineum, lower abdomen, penis (especially at the tip), testis, rectum, or and the lower back.</li><li>Urinary symptoms (including dysuria, frequency, hesitancy, urgency, and poor stream).</li></ul></li><li>A diagnosis of chronic prostatitis should be made based on the man's history and the exclusion of other conditions that may be causing symptoms such as:<ul><li>Urinary tract infection.</li><li>Urethritis.</li><li>Epididymo-orchitis.</li><li>Epididymitis.</li><li>Benign prostatic hypertrophy.</li><li>Cancer of the prostate, bladder, or colon.</li><li>Urethral stricture.</li><li>Obstructive calculus or a foreign body in the urinary tract.</li></ul></li><li>The presence of recurrent or relapsing urinary tract infections usually indicates the presence of CBP.</li><li>Men with suspected CBP should be referred to urology for specialist assessment and management. While awaiting referral:<ul><li>A single course of antibiotics should be prescribed.</li><li>If the man is in pain, paracetamol and/or a nonsteroidal anti-inflammatory drug (NSAID) should be prescribed.</li><li>If defecation is painful — a stool softener such as lactulose or docusate should be prescribed.</li></ul></li><li>For men with suspected CP/CPPS management options in primary care include:<ul><li>Referral to a urologist if there is diagnostic uncertainty or the man's symptoms are severe (use clinical judgement to determine the urgency of referral).</li><li>Prescribing paracetamol and/or an NSAID for pain relief.</li><li>Prescribing a stool softener such as lactulose or docusate if defecation is painful.</li><li>Offering a 4–6 week trial of an alpha-blocker if significant lower urinary tract symptoms are present.</li><li>Offering a single course of antibiotics, if symptoms have been present for less than 6 months.</li></ul></li><li>If symptoms persist, men with CP/CPPS should be referred to a urologist for specialist assessment and management.</li></ul><!-- end field df8e4bd4-9e5a-4a3b-85ef-79ffadf21852 --><!-- end item 6ddf2816-262a-432f-a8b1-f24c41e8c03b -->","topic":{"id":"c4c9527b-558e-5f8e-bc17-8e290dcde258","topicId":"e7c47213-5bd0-4104-8047-fdc108a48fed","topicName":"Prostatitis - chronic","slug":"prostatitis-chronic","aliases":[],"chapters":[{"id":"db8b7f60-5def-5da6-8f5a-97b134fe81af","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"261b0e99-ad07-59aa-82ad-fa8c5e297c03","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"191f6daf-33c8-5a36-9298-deb70f2118f9","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"3196f07a-652b-594b-a01b-c5adf6819612","slug":"changes","fullItemName":"Changes"},{"id":"cb3c96a5-276d-5602-88a2-6fe23e9db68a","slug":"update","fullItemName":"Update"}]},{"id":"71da42c9-a078-59ae-90c6-752133b53212","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"aec7f6cf-32f0-5cb8-997e-4fef498eea4a","slug":"goals","fullItemName":"Goals"},{"id":"3afbaae7-ae1e-5df4-87a4-e8fcadd24ce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"87d31fcb-2e1a-5f5f-b2b3-3cebf26dbf5e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b0e77d09-ef7a-52ce-a61d-d74872fcd77f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"73212593-e3d8-52ec-9384-1ee26a9e0290","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"59aaca07-0adb-5035-afea-fd747f067bc8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"864060e0-9a10-5069-9b80-daf6551f49b4","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"120b86df-be4c-54e8-ab8a-7edcad60de73","slug":"definition","fullItemName":"Definition"},{"id":"a35c2de7-75f2-59f4-9df6-6115e92ac1f7","slug":"causes","fullItemName":"Causes"},{"id":"3aa8e065-e5d9-587b-92fa-8e1824a53f6e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"34308471-71dc-5ccd-bf18-de90bce09174","slug":"prognosis","fullItemName":"Prognosis"},{"id":"6bcf89d2-7be0-5893-bcef-296b2b00b23e","slug":"complications","fullItemName":"Complications"}]},{"id":"e0b8b43d-8013-564a-b64b-23866b939127","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"5803967f-79d1-596c-8fb4-58eb0581f053","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"2901399a-1d1a-5b5e-ba74-a8e2973308cc","slug":"assessment","fullItemName":"Assessment"},{"id":"07fe1726-43db-50e8-854d-9e8d2048398c","slug":"investigations","fullItemName":"Investigations"},{"id":"3cf83ed6-63bf-58b4-97f7-98cd7d6815da","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dc9db115-7acf-5a8a-9dd1-f6bf8dd93454","slug":"management","fullItemName":"Management","subChapters":[{"id":"dbc1e2eb-5ed6-5e3b-9aa6-6f4a53bae15e","slug":"managing-chronic-prostatitis","fullItemName":"Scenario: Managing chronic prostatitis"}]},{"id":"c609cd7e-5825-5ffb-83e8-ba87b7f7806d","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"035b193a-907c-5212-99c7-e8a8926b1594","slug":"paracetamol-ibuprofen-codeine","fullItemName":"Paracetamol, ibuprofen, and codeine"},{"id":"f4e7b4f3-38ad-521e-bb43-4c48ac37724f","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"24c19a61-fe65-594c-a4e5-ab3b500281e4","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"2a603a06-dc49-5056-bf3b-1492b6300035","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39e951b0-a3a9-5bae-8465-8d5b1ac9504b","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"d8eb1d6d-d3f5-593e-bcbc-4214d26beee2","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"a9bd9455-225c-5705-8101-1b4f3177119c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3984c05f-a691-5d06-9587-785be5667206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e6bedf32-0ef7-5118-b6e2-fc3c2631a8c3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"1405259b-4bc7-5907-af93-234db06e958f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ad44cee6-1d13-5c9e-9587-6de26a5b22fd","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"160b464d-6dc9-5bb7-9156-90aa025b130c","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"c4c9527b-558e-5f8e-bc17-8e290dcde258","topicId":"e7c47213-5bd0-4104-8047-fdc108a48fed","topicName":"Prostatitis - chronic","slug":"prostatitis-chronic","aliases":[],"topicSummary":"Chronic prostatitis is characterized by at least 3 months of pain in the perineum or pelvic floor, often associated with lower urinary tract symptoms","lastRevised":"Last revised in September 2019","nextPlannedReviewBy":"2024-09-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2024-08","nextPlannedReviewByDisplay":"August 2024","specialities":[{"id":"f72b3ad6-0501-5364-8469-e48bd9b988b9","name":"Kidney disease and urology","slug":"kidney-disease-urology"},{"id":"34b90622-9d68-500d-98a2-3c80efbae845","name":"Men's health","slug":"mens-health"}],"chapters":[{"id":"db8b7f60-5def-5da6-8f5a-97b134fe81af","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"261b0e99-ad07-59aa-82ad-fa8c5e297c03","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"191f6daf-33c8-5a36-9298-deb70f2118f9","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"3196f07a-652b-594b-a01b-c5adf6819612","slug":"changes","fullItemName":"Changes"},{"id":"cb3c96a5-276d-5602-88a2-6fe23e9db68a","slug":"update","fullItemName":"Update"}]},{"id":"71da42c9-a078-59ae-90c6-752133b53212","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"aec7f6cf-32f0-5cb8-997e-4fef498eea4a","slug":"goals","fullItemName":"Goals"},{"id":"3afbaae7-ae1e-5df4-87a4-e8fcadd24ce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"87d31fcb-2e1a-5f5f-b2b3-3cebf26dbf5e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b0e77d09-ef7a-52ce-a61d-d74872fcd77f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"73212593-e3d8-52ec-9384-1ee26a9e0290","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"59aaca07-0adb-5035-afea-fd747f067bc8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"864060e0-9a10-5069-9b80-daf6551f49b4","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"120b86df-be4c-54e8-ab8a-7edcad60de73","slug":"definition","fullItemName":"Definition"},{"id":"a35c2de7-75f2-59f4-9df6-6115e92ac1f7","slug":"causes","fullItemName":"Causes"},{"id":"3aa8e065-e5d9-587b-92fa-8e1824a53f6e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"34308471-71dc-5ccd-bf18-de90bce09174","slug":"prognosis","fullItemName":"Prognosis"},{"id":"6bcf89d2-7be0-5893-bcef-296b2b00b23e","slug":"complications","fullItemName":"Complications"}]},{"id":"e0b8b43d-8013-564a-b64b-23866b939127","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"5803967f-79d1-596c-8fb4-58eb0581f053","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"2901399a-1d1a-5b5e-ba74-a8e2973308cc","slug":"assessment","fullItemName":"Assessment"},{"id":"07fe1726-43db-50e8-854d-9e8d2048398c","slug":"investigations","fullItemName":"Investigations"},{"id":"3cf83ed6-63bf-58b4-97f7-98cd7d6815da","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dc9db115-7acf-5a8a-9dd1-f6bf8dd93454","slug":"management","fullItemName":"Management","subChapters":[{"id":"dbc1e2eb-5ed6-5e3b-9aa6-6f4a53bae15e","slug":"managing-chronic-prostatitis","fullItemName":"Scenario: Managing chronic prostatitis"}]},{"id":"c609cd7e-5825-5ffb-83e8-ba87b7f7806d","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"035b193a-907c-5212-99c7-e8a8926b1594","slug":"paracetamol-ibuprofen-codeine","fullItemName":"Paracetamol, ibuprofen, and codeine"},{"id":"f4e7b4f3-38ad-521e-bb43-4c48ac37724f","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"24c19a61-fe65-594c-a4e5-ab3b500281e4","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"2a603a06-dc49-5056-bf3b-1492b6300035","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39e951b0-a3a9-5bae-8465-8d5b1ac9504b","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"d8eb1d6d-d3f5-593e-bcbc-4214d26beee2","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"a9bd9455-225c-5705-8101-1b4f3177119c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3984c05f-a691-5d06-9587-785be5667206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e6bedf32-0ef7-5118-b6e2-fc3c2631a8c3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"1405259b-4bc7-5907-af93-234db06e958f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ad44cee6-1d13-5c9e-9587-6de26a5b22fd","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"160b464d-6dc9-5bb7-9156-90aa025b130c","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"c4c9527b-558e-5f8e-bc17-8e290dcde258"}},"staticQueryHashes":["3666801979"]}